Conformation Dependent Anti-major Outer Membrane Protein (MOMP) Monoclonal Antibody BD5


A murine hybridoma expressing mAb BD3 was found to react with a conformationally dependent epitope on the chlamydial Major Outer Membrane Protein (MOMP), a primary target of neutralizing antibodies and vaccine development. The BD3 neutralized the in vitro infectivity of C. trachomatis serovars B, Ba, D, E, L2. It is useful for verifying the correct conformation of MOMP in vaccines against chlamydia trachomatis, Serovars B, BA, D, E, AND L2.

Potential Commercial Applications: Competitive Advantages:
  • A research material that can be used in the development of assays, validation of products or in quality control.
 
  • Speed up product development with NIH developed material that has already been tested and validated.


Inventors:

Harlan Caldwell (NIAID)  ➽ more inventions...


Intellectual Property:
Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2007-121)

Licensing Contact:
Charles Rainwater,
Email: crainwater@niaid.nih.gov
Phone: 301-496-2644

OTT Reference No: E-296-2007-0
Updated: Dec 4, 2017